ArticlePloS one2014
Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.Frontiers in immunology · 2018Trial
- Diagnostic Performance of ANCA Testing Across Three Platforms with and without Coexisting ANA Positivity: Experience from a Tertiary Healthcare Centre in India.Mediterranean journal of rheumatology · 2025Article
- Clinical Validity of Anti-Proteinase 3 Antibodies in Patients with Inflammatory Bowel Disease: A Short Meta-Analysis.Diagnostics (Basel, Switzerland) · 2023Review
- Performance of two multiplex flow cytometric assays for antibody detection in Egyptian patients.African journal of laboratory medicine · 2023Article
- PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.Auto- immunity highlights · 2020Review
- Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn's Disease.Journal of Crohn's & colitis · 2019Article
- Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.Clinical reviews in allergy & immunology · 2017Review
- [Paradigm shift in ANCA diagnostics : New international consensus recommendations].Zeitschrift fur Rheumatologie · 2017Review
- Simultaneous detection of celiac disease-specific IgA antibodies and total IgA.Auto- immunity highlights · 2016Article
- Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis.Medicine · 2016Article
- Automation, consolidation, and integration in autoimmune diagnostics.Auto- immunity highlights · 2015Article
- Diagnostics and environmental factors.Immunologic research · 2015Article
- Correction: Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA.PloS one · 2015Article
- Correction: simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.PloS one · 2015Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-neutrophil cytoplasmic antibodies (ANCA) are the serological hallmark of small vessel vasculitis, so called ANCA-associated vasculitis. The international consensus requires testing by indirect immunofluorescence (IIF) on human ethanol-fixed neutrophils (ethN) as screening followed by confirmation with enzyme-linked immunosorbent assays (ELISAs). This study evaluates the combination of cell- and microbead-based digital IIF analysis of ANCA in one reaction environment by the novel multiplexing CytoBead technology for simultaneous screening and confirmatory ANCA testing. Sera of 592 individuals including 118 patients with ANCA-associated vasculitis, 133 with rheumatoid arthritis, 49 with infectious diseases, 77 with inflammatory bowel syndrome, 20 with autoimmune liver diseases, 70 with primary sclerosing cholangitis and 125 blood donors were tested for cytoplasmic ANCA (C-ANCA) and perinuclear ANCA (P-ANCA) by classical IIF and ANCA to proteinase 3 (PR3) and myeloperoxidase (MPO) by ELISA. These findings were compared to respective ANCA results determined by automated multiplex CytoBead technology using ethN and antigen-coated microbeads for microbead immunoassays. There was a good agreement for PR3- and MPO-ANCA and a very good one for P-ANCA and C-ANCA by classical and multiplex analysis (Cohen's kappa [κ] = 0.775, 0.720, 0.876, 0.820, respectively). The differences between classical testing and CytoBead analysis were not significant for PR3-ANCA, P-ANCA, and C-ANCA (p<0.05, respectively). The prevalence of confirmed positive ANCA findings by classical testing (IIF and ELISA) compared with multiplex CytoBead analysis (IIF and microbead immunoassay positive) resulted in a very good agreement (κ = 0.831) with no significant difference of both methods (p = 0.735). Automated endpoint-ANCA titer detection in one dilution demonstrated a very good agreement with classical analysis requiring dilution of samples (κ = 0.985). Multiplexing by CytoBead technology can be employed for simultaneous screening and quantitative confirmation of ANCA. This novel technique provides fast and cost-effective ANCA analysis by automated digital IIF for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.